Literature DB >> 33453720

The combination of atorvastatin with silymarin enhances hypolipidemic, antioxidant and anti-inflammatory effects in a rat model of metabolic syndrome.

I Marková1, H Malínská, M Hüttl, D Miklánková, O Oliyarnyk, M Poruba, Z Rácová, L Kazdová, R Večeřa.   

Abstract

Hypolipidemic and cardioprotective effects of statins can be associated with the development of myopathies and new-onset type 2 diabetes. These adverse effects may be related to increased oxidative stress. The plant extract silymarin (SM) is known for its antioxidant and anti-inflammatory actions. We tested the hypothesis that the combination of atorvastatin (ATV) with SM could improve therapy efficacy and eliminate some negative effects of statin on hypertriglyceridemia-induced metabolic disorders. Hereditary hypertriglyceridemic rats were fed a standard diet for four weeks without supplementation; supplemented with ATV (5 mg/kg b. wt./day) or a combination of ATV with 1 % micronized SM (ATV+SM). ATV treatment elevated plasma levels of HDL-cholesterol (p<0.01), glucose and insulin and decreased triglycerides (p<0.001). The combination of ATV+SM led to a significant reduction in insulin, an improvement of glucose tolerance, and the hypolipidemic effect was enhanced compared to ATV alone. Furthermore, ATV supplementation increased skeletal muscle triglycerides but its combination with SM decreased triglycerides accumulation in the muscle (p<0.05) and the liver (p<0.01). In the liver, ATV+SM treatment increased the activities of antioxidant enzymes, glutathione and reduced lipid peroxidation (p<0.001). The combined administration of ATV with SM potentiated the hypolipidemic effect, reduced ectopic lipid accumulation, improved glucose metabolism, and increased antioxidant and anti-inflammatory actions. Our results show that SM increased the effectiveness of statin therapy in a hypertriglyceridemic rat model of metabolic syndrome.

Entities:  

Mesh:

Substances:

Year:  2021        PMID: 33453720      PMCID: PMC8820516          DOI: 10.33549/physiolres.934587

Source DB:  PubMed          Journal:  Physiol Res        ISSN: 0862-8408            Impact factor:   1.881


  38 in total

Review 1.  The Role of Nutraceuticals in Statin Intolerant Patients.

Authors:  Maciej Banach; Angelo Maria Patti; Rosaria Vincenza Giglio; Arrigo F G Cicero; Atanas G Atanasov; Gani Bajraktari; Eric Bruckert; Olivier Descamps; Dragan M Djuric; Marat Ezhov; Zlatko Fras; Stephan von Haehling; Niki Katsiki; Michel Langlois; Gustavs Latkovskis; G B John Mancini; Dimitri P Mikhailidis; Olena Mitchenko; Patrick M Moriarty; Paul Muntner; Dragana Nikolic; Demosthenes B Panagiotakos; Gyorgy Paragh; Bernhard Paulweber; Daniel Pella; Christos Pitsavos; Željko Reiner; Giuseppe M C Rosano; Robert S Rosenson; Jacek Rysz; Amirhossein Sahebkar; Maria-Corina Serban; Dragos Vinereanu; Michal Vrablík; Gerald F Watts; Nathan D Wong; Manfredi Rizzo
Journal:  J Am Coll Cardiol       Date:  2018-07-03       Impact factor: 24.094

2.  SREBP-2: a link between insulin resistance, hepatic cholesterol, and inflammation in NASH.

Authors:  Derrick M Van Rooyen; Geoff C Farrell
Journal:  J Gastroenterol Hepatol       Date:  2011-05       Impact factor: 4.029

3.  Metformin attenuates myocardium dicarbonyl stress induced by chronic hypertriglyceridemia.

Authors:  H Malinska; V Škop; J Trnovska; I Markova; P Svoboda; L Kazdova; M Haluzik
Journal:  Physiol Res       Date:  2017-11-10       Impact factor: 1.881

Review 4.  Mechanisms of statin-associated skeletal muscle-associated symptoms.

Authors:  Jamal Bouitbir; Gerda M Sanvee; Miljenko V Panajatovic; François Singh; Stephan Krähenbühl
Journal:  Pharmacol Res       Date:  2019-03-12       Impact factor: 7.658

5.  Silymarin improved diet-induced liver damage and insulin resistance by decreasing inflammation in mice.

Authors:  Yu Guo; Suli Wang; Ying Wang; Tiehong Zhu
Journal:  Pharm Biol       Date:  2016-07-08       Impact factor: 3.503

6.  Statins and risk of incident diabetes: a collaborative meta-analysis of randomised statin trials.

Authors:  Naveed Sattar; David Preiss; Heather M Murray; Paul Welsh; Brendan M Buckley; Anton J M de Craen; Sreenivasa Rao Kondapally Seshasai; John J McMurray; Dilys J Freeman; J Wouter Jukema; Peter W Macfarlane; Chris J Packard; David J Stott; Rudi G Westendorp; James Shepherd; Barry R Davis; Sara L Pressel; Roberto Marchioli; Rosa Maria Marfisi; Aldo P Maggioni; Luigi Tavazzi; Gianni Tognoni; John Kjekshus; Terje R Pedersen; Thomas J Cook; Antonio M Gotto; Michael B Clearfield; John R Downs; Haruo Nakamura; Yasuo Ohashi; Kyoichi Mizuno; Kausik K Ray; Ian Ford
Journal:  Lancet       Date:  2010-02-16       Impact factor: 79.321

7.  Effects of pravastatin and bezafibrate on biliary lipid excretion and hepatic expression of Abcg5 and Abcg8 in the rat.

Authors:  Toshinori Kamisako; Hiroshi Ogawa
Journal:  J Gastroenterol Hepatol       Date:  2004-08       Impact factor: 4.029

Review 8.  Association Between Lowering LDL-C and Cardiovascular Risk Reduction Among Different Therapeutic Interventions: A Systematic Review and Meta-analysis.

Authors:  Michael G Silverman; Brian A Ference; Kyungah Im; Stephen D Wiviott; Robert P Giugliano; Scott M Grundy; Eugene Braunwald; Marc S Sabatine
Journal:  JAMA       Date:  2016-09-27       Impact factor: 56.272

9.  Increased liver oxidative stress and altered PUFA metabolism precede development of non-alcoholic steatohepatitis in SREBP-1a transgenic spontaneously hypertensive rats with genetic predisposition to hepatic steatosis.

Authors:  Hana Malínská; Olena Oliyarnyk; Miriam Hubová; Václav Zídek; Vladimír Landa; Miroslava Simáková; Petr Mlejnek; Ludmila Kazdová; Theodore W Kurtz; Michal Pravenec
Journal:  Mol Cell Biochem       Date:  2009-09-12       Impact factor: 3.396

Review 10.  Human C-reactive protein and the metabolic syndrome.

Authors:  Sridevi Devaraj; Uma Singh; Ishwarlal Jialal
Journal:  Curr Opin Lipidol       Date:  2009-06       Impact factor: 4.776

View more
  2 in total

Review 1.  A Comprehensive Review of the Cardiovascular Protective Properties of Silibinin/Silymarin: A New Kid on the Block.

Authors:  Nikolaos P E Kadoglou; Chrystalla Panayiotou; Michail Vardas; Nikolaos Balaskas; Nikolaos G Kostomitsopoulos; Alexandra K Tsaroucha; Georgia Valsami
Journal:  Pharmaceuticals (Basel)       Date:  2022-04-27

2.  The Beneficial Additive Effect of Silymarin in Metformin Therapy of Liver Steatosis in a Pre-Diabetic Model.

Authors:  Martina Hüttl; Irena Markova; Denisa Miklankova; Iveta Zapletalova; Martin Poruba; Zuzana Racova; Rostislav Vecera; Hana Malinska
Journal:  Pharmaceutics       Date:  2021-12-27       Impact factor: 6.321

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.